It’s Time to Invest in Cancer Biotech Ignyta
October 27, 2016 – https://seekingalpha.com
As a result of being in the healthcare profession and having the advantage of picking doctors’ brains about various drugs in development, I am loading up on the little-known, small-cap precision medicine company Ignyta (NASDAQ:RXDX). Ignyta made a big splash last year at the American Society of Clinical Oncology (ASCO) meeting…
In Turnaround Saga, Ignyta Nears Crucial Phase in Cancer Drug Trial
September 23rd, 2016 – https://www.xconomy.com
Biotech CEO Jonathan Lim co-founded Ignyta in 2011 to commercialize a new approach to diagnosing and treating rheumatoid arthritis, based on discoveries that showed how changes in methyl group molecules associated with the human genome could change the way genes function.
Ignyta Hopes Its Drug Results Will Trump Previous Bad Timing
September 5th, 2016 – https://www.sdbj.com
Few biotechs were untouched by the gloomy market conditions of the past year, and local drugmaker Ignyta Inc. was no exception. But despite the company’s fall from the limelight, Ignyta could be nurturing a valuable asset — and one that analysts believe is being overlooked.
Ignyta Is Proof That Biotech Bargains Still Exist
August 13th, 2016 – https://seekingalpha.com
With the biotech sector becoming red hot again, it can be hard for investors to find stocks with significant upside. I try to identify companies that are undervalued, have an advanced pipeline and are prime candidates to get acquired or establish lucrative partnerships…There has never been a company with a billion dollar a year drug that has not been acquired or become a huge company.
Ignyta, One of ASCO’s Biggest Winners, Was A Complete Unknown Three Months Ago
June 9, 2015 – https://www.forbes.com
Little-known Ignyta (RXDX) has received quite a bit of attention from the Street in the week since the American Society of Clinical Oncology’s annual meeting wrapped up. The stock has doubled – to a market cap of $450 million – and where RXDX rarely traded more than 30,000 shares on any day three months ago, the equity did 12 million shares over just two days after ASCO.